We could not find any results for:
Make sure your spelling is correct or try broadening your search.
(OTC:AGTX), is a clinical-stage biotechnology company that is pursuing the development of a comprehensive suite of novel, science-driven, biopharmaceuticals that target the endocannabinoid system across multiple therapeutic areas with greater market exclusivity, for the treatment of metabolic diseas... (OTC:AGTX), is a clinical-stage biotechnology company that is pursuing the development of a comprehensive suite of novel, science-driven, biopharmaceuticals that target the endocannabinoid system across multiple therapeutic areas with greater market exclusivity, for the treatment of metabolic diseases; including Type 2 Diabetes Mellitus, Chronic Obesity, Non-alcoholic Fatty Liver Disease (NAFLD), and Non-alcoholic Steatohepatitis (NASH). AGENTIX acquired specific assets and licensing rights, including licensing rights associated with intellectual property as part of Worldwide Exclusive Agreements with NHRI (National Heath Research Institute) and RTI (Research Triangle Institute) International. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.1601 | 0.18005 | 0.1601 | 500 | 0.17606 | CS |
4 | -0.0798 | -33.2638599416 | 0.2399 | 0.46 | 0.1517 | 13144 | 0.23177107 | CS |
12 | 0.0101 | 6.73333333333 | 0.15 | 0.46 | 0.0361 | 20439 | 0.18627106 | CS |
26 | 0.1201 | 300.25 | 0.04 | 0.46 | 0.0261 | 18875 | 0.14212633 | CS |
52 | 0.1111 | 226.734693878 | 0.049 | 0.46 | 0.021 | 20623 | 0.10800074 | CS |
156 | -0.402 | -71.5175235723 | 0.5621 | 0.8998 | 0.021 | 8097 | 0.12309378 | CS |
260 | -2.2599 | -93.3842975207 | 2.42 | 5 | 0.0001 | 5125 | 0.32108708 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions